Top Story

Pertuzumab conferred ‘unprecedented’ OS benefit in HER-2–positive metastatic breast cancer

October 2, 2014

The addition of pertuzumab to trastuzumab and docetaxel prolonged OS by nearly 16 months in patients with HER-2–positive metastatic breast cancer, according to final OS results of the CLEOPATRA study presented at the European Society for Medical Oncology Annual Congress in Madrid.

“The results of the CLEOPATRA study suggest that all patients who have newly diagnosed metastatic or advanced HER-2–positive breast cancer should be given the opportunity to have treatment with dual antibody therapy with trastuzumab and pertuzumab with chemotherapy,” Sandra M. Swain, MD, FACP, medical director of Washington Cancer Institute of the MedStar Washington Hospital Center, told HemOnc Today. “These results are phenomenal. We have not seen these kind of survival results in the metastatic disease setting in the past. The other very important aspect is that this could predict a mortality reduction in the adjuvant setting which will be reported in the APHINITY trial sometime in the next couple of years.”

In the Journals

Adjuvant FOLFOX extended DFS in locally advanced rectal cancer

October 2, 2014
The addition of oxiliplatin to fluorouracil and leucovorin extended DFS among patients with locally advanced rectal cancer who underwent preoperative chemotherapy and…
Institution Notes

AACR presents research award

October 1, 2014
Graham A. Colditz, MD, DrPH, received the American Association for Cancer Research’s 2014 AACR Award for Outstanding Achievement in Cancer Prevention…

Just-in-Time management principles helped reduce patient wait time

October 1, 2014
Applying processes used in manufacturing to streamline patient flow can successfully reduce patient wait time and increase the confidence of residents at teaching…
More News Headlines »

Applying Imaging, Biomarkers, and Immunotherapy in the Management of NSCLC

This activity is supported by an educational grant from Genentech, Inc.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, but the numerous subtypes make this disease…
More »
Meeting News Coverage Video

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »